Evidence map›Paper›PMID 32397561›Full record

ArticleInternational journal of molecular sciences2020

Selective Activation of ZAK β Expression by 3-Hydroxy-2-Phenylchromone Inhibits Human Osteosarcoma Cells and Triggers Apoptosis via JNK Activation.

Chien-Yao Fu, Ing-Shiow Lay, Marthandam Asokan Shibu, Yan-Shen Tseng, Wei-Wen Kuo, Jaw-Ji Yang, Tso-Fu Wang, B Mahalakshmi Bharath, Yu-Lan Yeh, Chih-Yang Huang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Chien-Yao FuOrthopaedic Department, Armed Forces General Hospital, Taichung 411, Taiwan.ORCID 0000-0003-3403-2943
Ing-Shiow LaySchool of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung 404, Taiwan.
Marthandam Asokan ShibuCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.
Yan-Shen TsengGraduate Institute of Biomedical Science, China Medical University, Taichung 404, Taiwan.
Wei-Wen KuoDepartment of Biological Science and Technology, China Medical University, Taichung 404, Taiwan.ORCID 0000-0002-2097-2240
Jaw-Ji YangSchool of Dentistry, Chung-Shan Medical University, Taichung 402, Taiwan.
Tso-Fu WangDepartment of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.
B Mahalakshmi BharathInstitute of Research and Development, Duy Tan University, Da Nang 550000, Vietnam.
Yu-Lan YehDepartment of Pathology, Changhua Christian Hospital, Changhua 500, Taiwan.ORCID 0000-0001-8703-7786
Chih-Yang HuangGraduate Institute of Biomedical Science, China Medical University, Taichung 404, Taiwan.
China Medical University · TWAsia University · TWChung Shan Medical University · TWDuy Tan University · VNKang-Ning Junior College of Medical Care and Management · TWTaichung Armed Forces General Hospital · TWTzu Chi Foundation · TWTzu Chi University · TW

Funding

China Medical University, Taiwan CMU101-ASIA-08
6 · The paper itself

Abstract

Although various advancements in radical surgery and neoadjuvant chemotherapy have been developed in treating osteosarcoma (OS), their clinical prognosis remains poor. A synthetic chemical compound, 3-hydroxylflavone, that is reported to regulate ROS production is known to inhibit human bone osteosarcoma cells. However, its role and mechanism in human OS cells remains unclear. In this study, we have determined the potential of 3-Hydroxy-2-phenylchromone (3-HF) against OS using human osteosarcoma (HOS) cells. Our previous studies showed that Zipper sterile-alpha-motif kinase (ZAK), a kinase member of the MAP3K family, was involved in various cellular events such as cell proliferation and cell apoptosis, and encoded two transcriptional variants, ZAKα and β. In this study, we show that 3-HF induces the expression of ZAK and thereby enhances cellular apoptosis. Using gain of function and loss of function studies, we have demonstrated that ZAK activation by 3-HF in OS cells is confined to a ZAKβ form that presumably plays a leading role in triggering ZAKα expression, resulting in an aggravated cancer apoptosis. Our results also validate ZAKβ as the predominant form of ZAK to drive the anticancer mechanism in HOS cells.

Indexed as

Antineoplastic AgentsApoptosisBone NeoplasmsCaspase 3Cell Line, TumorEnzyme ActivationFlavonoidsGain of Function MutationHumansLoss of Function MutationMAP Kinase Kinase 4MAP Kinase Kinase KinasesMembrane Potential, MitochondrialOsteosarcomaProtein IsoformsSignal Transduction3-hydroxyflavoneAntineoplastic AgentsCASP3 protein, humanCaspase 3FlavonoidsMAP3K20 protein, humanMAP Kinase Kinase 4MAP Kinase Kinase KinasesProtein Isoforms3-Hydroxy-2-phenylchromoneapoptosisosteosarcomaZAKβ

Identifiers

PMID32397561
PMCPMC7247666
OpenAlexW3023946594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.